A phase 3 clinical trial published in the New England Journal of Medicine has tested a two-drug combination — anbenitamab and HB1801 — in patients with HER2-positive advanced breast cancer.
The New England Journal of Medicine has published results from the HEALER trial, a phase 3 study examining whether combining anbenitamab and HB1801 can improve outcomes for patients with HER2-positive (human epidermal growth factor receptor 2-positive) advanced breast cancer. HER2-positive breast cancer is a type where the tumour has higher-than-normal levels of a protein that drives cancer cell growth.
The journal also published an accompanying editorial titled Targeting HER2 — A Triumph of Science, suggesting the findings are considered medically significant within the oncology (cancer treatment) research community.
The NEJM post did not include trial outcome figures or patient numbers in the tweet itself, and the full data sit behind the journal’s publication. According to the journal, both pieces appear under its oncology category.
No specific results, survival figures, or side-effect data from the HEALER trial were included in the publicly available tweet. Readers seeking detail on the trial’s findings would need to access the full journal article directly through their GP, a hospital specialist, or a medical library.
Anyone concerned about breast cancer symptoms or their own treatment options should speak to their GP or call NHS 111. People already under the care of an oncology team with questions about emerging treatments are best placed to raise them at their next clinical appointment.
—
NHS 111 is available 24 hours a day, seven days a week, for health queries that are not emergencies. In an emergency, call 999.
Source: @NEJM